Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and six months ending September 30, 2025, on October 24, 2025, following a board meeting. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss the company’s financial performance. This announcement is significant for stakeholders as it provides insights into the company’s recent financial health and strategic direction.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories’ overall stock score reflects strong financial performance and strategic growth initiatives, tempered by technical analysis signals and challenges in the U.S. generics market. The company’s valuation is fair, and while the earnings call presented mixed results, the strategic focus on biosimilars and environmental leadership are positive indicators.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, primarily engaged in manufacturing and marketing a wide range of generic medicines, active pharmaceutical ingredients, and proprietary products. The company is headquartered in Hyderabad, India, and is listed on multiple stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 1,106,380
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.9B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.